Technology

A treatment method that can cause most of the cancer cells to self-destruct simply by injecting molecules is born


Science

A treatment method that can cause most of the cancer cells to self-destruct simply by injecting molecules is born

by Trust "Tru" Katsande

Pancreatic cancerIs difficult to detect early among cancers, and progresses quickly.5-year survival rateIs also known for being very low. Researchers in Israel have found a way to kill such pancreatic cancer cells by injecting certain molecules into the body and reduce it by 80-90%.

Oncotarget | The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=27268

In possible breakthrough, molecule destroys pancreatic cancer cells in mice | The Times of Israel
https://www.timesofisrael.com/in-possible-breakthrough-molecule-destroys-pancreatic-cancer-cells-in-mice/

Israeli Study Finds Molecule That Triggers Self-Destruction Of Pancreatic Cancer Cells | Health News
https://nocamels.com/2019/12/israeli-study-molecule-destruction-pancreatic-cancer-cells/


Tel Aviv UniversityofMalca Cohen-ArmonWith the professorSheba Medical CenterofTalia GolanThe researchers, led by Drs., Experimented with a new technique for self-destructing human pancreatic cancer cells in 24 mice whose immunity was suppressed so as not to reject foreign cells.

The research team divided the 24 mice into eight groups of eight, and inserted human pancreatic cancer cells as xenografts into each mouse. It took about 15 days for the pancreatic cancer cells to grow in the mouse.

Later, the team developed two groups to treat stroke patients.PJ34"Was injected into the blood. PJ34 is associated with cerebral ischemiaMicrogliaIt has been reported that it suppresses the activation of cancer and prevents neuronal cell death, but according to Professor Cohen-Armon, there have been no cases used to treat cancer so far. Of the groups receiving PJ34, one group received five doses per week and the other received three doses per week. A third control group received saline infusions five times a week.

by Shutterbug75

Mice were administered PJ34 and saline over a three-week period, and at the end of the study, the group receiving PJ34 five times a week showed a change in tumor size that was reduced by approximately 40%. In addition, a study of pancreatic cancer cells in mice 30 days after treatment with PJ34 showed that pancreatic cancer cells were reduced by 80-90% in both groups receiving PJ34. It turns out. The results showed that PJ34 significantly reduced human-derived pancreatic cancer cells in mice. In addition, in the group that received PJ34 five times a week, it was reported that the tumor disappeared completely in one mouse on day 56 after the start of treatment.

"PJ34 penetrates the cell membrane, but only affects human cancer cells. This molecule causes abnormalities in the replication of human cancer cells, resulting in a rapid rate," said Cohen-Armon. Cell death occurs, so it can be said that the growth of cancer cells itself has led to the death of cancer cells. "

In addition, the team argued that PJ34 had an exclusive effect on human pancreatic cancer cells, but not other cells or benign cancer cells. During a series of studies, no remarkable changes such as side effects or weight gain were observed in each mouse, and no abnormal behavior was confirmed. "Efficient eradication of malignant cells against human pancreatic cancer cell grafts represents a new model for pancreatic cancer treatment," the researchers commented.

by luvqs

In an experiment conducted in parallel with this study, the research team found that PJ34 also works efficiently on multiple aggressive cancer cells other than pancreatic cancer. Professor Cohen-Armon said he would like to use larger animals to test the effects of PJ34 in future studies and ultimately test for therapeutic effects on humans.

Copy the title and URL of this article

Source link

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close